Substituted quinoxalines as FGFR kinase inhibitors

US10052320B2 · kind B2 · utility

Assignee

• ASTEX THERAPEUTICS LIMITED · GB

Inventors

• Steven John Woodhead · San Diego, US
• Christopher William Murray · Cambridge, GB
• Valerio Berdini · Cambridge, GB
• Gordon Saxty · Cambridge, GB
• Gilbert Ebai Besong · Bad Dürkheim, DE
• Lieven Meerpoel · Beerse, BE
• Olivier Alexis Georges Querolle · Évreux, FR
• Virginie Sophie Poncelet · Rodez, FR

Key dates

• Filing date: Feb 3, 2016
• Grant date: Aug 21, 2018
• Expiry date: Feb 3, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.